- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.03. | Excillum and Chugai Technos announce partnership to introduce advanced battery inspection systems in Japan | 5 | Cision News | ||
| 30.01. | Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech | 6 | FierceBiotech | ||
| 29.01. | Chugai Pharmaceutical FY2025 slides: Record profits amid pipeline evolution | 3 | Investing.com | ||
| 29.01. | Chugai: Rekordgewinn im Geschäftsjahr 2025 - Pipeline-Anpassung verunsichert Anleger | 10 | Investing.com Deutsch | ||
| 29.01. | Chugai Pharmaceutical: Rekordgewinne im Geschäftsjahr 2025, doch Aktie gibt nach | 3 | Investing.com Deutsch | ||
| CHUGAI PHARMACEUTICAL CO LTD ADR Aktie jetzt für 0€ handeln | |||||
| 29.01. | Chugai Pharmaceutical reports FY results | 2 | Seeking Alpha | ||
| 29.01. | Chugai Pharma FY25 Results Climb, Sees Growth In FY26 Core Profit, Revenues | 364 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) reported Thursday higher profit and revenues in fiscal 2025. The company further announced year-end dividends, and lower fiscal 2026... ► Artikel lesen | |
| 22.12.25 | Chugai Secures Regulatory Nod For Tecentriq In Thymic Carcinoma | 460 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Monday announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Tecentriq Intravenous Infusion for an... ► Artikel lesen | |
| 25.11.25 | Chugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DME | 421 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCF.PK) on Tuesday reported positive results from its phase I/II TEIEN study evaluating the Port Delivery System with Ranibizumab (PDS) in... ► Artikel lesen | |
| 25.11.25 | Chugai Pharmaceutical Teams With Biomy For Development Of AI-based Cancer Pathology Program | 485 | AFX News | TOKYO (dpa-AFX) - Chugai Pharmaceutical Co., Ltd. (CHGCY.PK), Tuesday announced a Memorandum of Understanding with Biomy, Inc., a provider of innovative services for pharmaceutical companies... ► Artikel lesen | |
| 06.11.25 | Rani Therapeutics announces $1.085 billion Chugai collaboration | 16 | Investing.com | ||
| 27.10.25 | Chugai acquires Renalys, enhancing its kidney disease portfolio | 3 | Pharmaceutical Technology | ||
| 24.10.25 | Chugai buys a kidney biotech; ICER targets rising launch prices | 4 | BioPharma Dive | ||
| 24.10.25 | Roche's Chugai strikes $200M M&A deal to take over IgAN asset in several Asian countries | 29 | FiercePharma | ||
| 24.10.25 | Chugai buys 'Asia lag' firm Renalys for $98m upfront | 3 | pharmaphorum | ||
| 24.10.25 | Chugai Pharmaceutical 9-month Net Income Rises | 449 | AFX News | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Chugai Pharmaceutical Co. reported, on a IFRS basis, nine month net income of 305.6 billion yen, up 3.3% from a year ago. Revenue was 911.6 billion yen,... ► Artikel lesen | |
| 23.10.25 | Roche axes 4 Chugai solid tumor assets in early-phase clearout | 10 | FierceBiotech | ||
| 17.10.25 | Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact | 12 | FierceBiotech | ||
| 17.10.25 | Rani Therapeutics surges on Chugai licensing deal, private placement | 32 | Seeking Alpha | ||
| 17.10.25 | Rani Therapeutics: Aktie schießt nach potenziellem Milliarden-Deal mit Chugai in die Höhe | 38 | Investing.com Deutsch |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TRULIEVE CANNABIS | 5,435 | +1,40 % | Trulieve Cannabis Corp.: Trulieve Reports Fourth Quarter and Full Year 2025 Results with 60% Gross Margin and Record Cash Flow Generation | Full year revenue of $1.2 billion, with 60% gross margin
Record 2025 cash flow from operations of $273 million and free cash flow of $229 million*
Record 50.1... ► Artikel lesen | |
| WEST PHARMACEUTICAL SERVICES | 204,00 | -3,68 % | West Pharmaceutical Services skizziert Wachstumsstrategie auf KeyBanc Forum | ||
| KALA BIO | 0,201 | +7,87 % | Red Light Holland Corp.: Red Light Holland Engages Kala Bio's Researgency.ai Platform to Support Clinical Development of Filament Health's Patented PEX010 Botanical Psilocybin Drug Candidate | AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio's purpose-built agentic AI platform for the biotechnology industryToronto... ► Artikel lesen | |
| SHIONOGI | 18,400 | +2,22 % | Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream | ||
| CHARLOTTES WEB | 0,580 | 0,00 % | Charlotte's Web Holdings Inc: Charlotte's Web to release 2025 results March 31 | ||
| BEXIMCO PHARMACEUTICALS | 0,450 | 0,00 % | Beximco Pharma: Gerichtsanhörung auf nach April verschoben | ||
| LUYE PHARMA | 0,256 | +1,59 % | LUYE PHARMA (02186): NOTICE OF BOARD MEETING | ||
| MIRUM PHARMACEUTICALS | 77,00 | +0,65 % | Citizens reiterates Mirum Pharmaceuticals stock rating ahead of data | ||
| PERCHERON THERAPEUTICS | 0,005 | +28,57 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 18.03.2026 | Das Instrument 5RR CA7502321002 RADIAL RESEARCH CORP. EQUITY wird cum Kapitalmassnahme gehandelt am 18.03.2026 und ex Kapitalmassnahme am 19.03.2026 The instrument 5RR CA7502321002 RADIAL RESEARCH CORP.... ► Artikel lesen | |
| AYURCANN | 0,001 | 0,00 % | CSE Bulletin: Suspensions - Planet Green Metals Inc., Ayurcann Holdings Corp. | Le 9 mars/March 2026
Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101... ► Artikel lesen | |
| AVANT BRANDS | 0,414 | +4,55 % | Avant Brands Inc.: Avant Brands Announces Strategic Realignment of European Operations and Reclaims BLK MKT Brand Rights in Germany and Switzerland | KELOWNA, BC / ACCESS Newswire / March 17, 2026 / Avant Brands Inc. (TSX:AVNT)(OTCQX:AVTBF)(FRA:1BU0) ("Avant" or the "Company"), a leading producer of ultra-premium cannabis products, today announced... ► Artikel lesen | |
| KALBE FARMA | 0,042 | -8,70 % | KLBF to buyback shares, allocating IDR 250 billion: KLBF plans to repurchase shares worth IDR 250 billion over ... | ||
| EVEREST MEDICINES | 4,120 | +10,16 % | Everest Medicines Limited: Everest Medicines Enters into Asset Purchase Agreement for Etripamil Nasal Spray, Expanding Cardiovascular Footprint | HONG KONG, Mar 25, 2026 - (ACN Newswire) - Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited ('CORXEL'). Under the... ► Artikel lesen | |
| KOBAYASHI PHARMACEUTICAL | 30,200 | +0,67 % | Kobayashi Pharmaceutical Co., Ltd. Profit Declines In Full Year | TOKYO (dpa-AFX) - Kobayashi Pharmaceutical Co., Ltd. (KBYPF) announced earnings for full year that Dropped, from last yearThe company's earnings came in at JPY3.656 billion, or JPY49.19 per... ► Artikel lesen | |
| SILO WELLNESS | 0,008 | -100,00 % | Silo Wellness Inc.: Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of Business | Eugene, Oregon and Toronto, Ontario--(Newsfile Corp. - September 28, 2025) - Silo Wellness Inc. (CSE: SILO) ("Silo" or the "Company"), to be renamed Born Defense Inc., is pleased to announce that it... ► Artikel lesen |
CHUGAI PHARMACEUTICAL CO LTD ADR gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +5,71 % bei einem Aktienkurs von 22,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CHUGAI PHARMACEUTICAL CO LTD ADR finden Sie auf Wallstreet Online.